Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SFPQ
REST API REST API
Homo sapiens
SFPQ is differentially expressed in 382 experiments: 162 organism parts: liver, placenta, ... (160 more);, 286 disease states: normal, colon carcinoma, ... (284 more);, 134 cell types 500 cell lines 58 compound treatments and 90 other conditions.
Synonyms PSF
Orthologs SFPQ (Bos taurus)   Sfpq (Mus musculus)   sfpq (Danio rerio)   Q91017_CHICK (Gallus gallus)   Sfpq (Rattus norvegicus)   F1M8Q6_RAT (Rattus norvegicus)   ENSCING00000004050 (Ciona intestinalis)   nonA-l (Drosophila melanogaster)   nonA (Drosophila melanogaster)   sfpq (Xenopus laevis)   XM_532566.2 (Canis familiaris)   ENSCAFG00000003595 (Canis familiaris)   ENSCAFG00000017608 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term RNA splicing, DNA binding, protein binding, DNA repair, regulation of transcription, DNA-dependent, alternative nuclear mRNA splicing, via spliceosome, nucleic acid binding, nuclear matrix, nucleus, DNA recombination, nucleotide binding, mRNA processing, nucleoplasm, RNA binding, paraspeckles
InterPro Term NOPS, RRM_dom
UniProt Accession P23246, Q9BSV4
Search EB-eye ENSG00000116560
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-MEXP-433, ... (35 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
primary culture
2
E-GEOD-2450, E-GEOD-1657
SNU16
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-6013, E-GEOD-3202
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC38
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
494 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (59 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD8+ T cell
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD4+ T cell
1
2
E-AFMX-5, E-GEOD-16190, E-TABM-145
CD19+ B cell
1
E-MEXP-1600
128 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (77 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
glioblastoma
3
E-GEOD-6014, E-MTAB-37, E-GEOD-4290
prostate carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-96, E-MEXP-1327
colon carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
280 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-GEOD-697, ... (36 experiments)

Factor Value U/D Experiments
none
7
9
E-MEXP-1601, E-GEOD-412, E-TABM-868, E-MEXP-1958, E-GEOD-2803, ... (16 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
SDF
1
E-GEOD-7307
ponasterone A
1
E-GEOD-3113
2-(3,4,5-trimethoxy-phenylamino)-pyrrolo[2,3-d]pyrimidines
1
1
E-GEOD-6932
52 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-860, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-7788, E-GEOD-22541, E-GEOD-22148, ... (9 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (44 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, ... (10 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-7540, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.281 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM